Multiple Myeloma Research Foundation (MMRF)
@themmrf.bsky.social
We are the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. themmrf.org
Day 1 at #IMS2025 is in the books!
The MMRF team is on the ground in Toronto, bringing you insights from the world’s largest myeloma meeting. From new therapies to strategies for high-risk patients, see our recap of day 1:
👉 themmrf.org/mmrf-blogs/i...
The MMRF team is on the ground in Toronto, bringing you insights from the world’s largest myeloma meeting. From new therapies to strategies for high-risk patients, see our recap of day 1:
👉 themmrf.org/mmrf-blogs/i...
IMS Annual Meeting - Day 1 - MMRF
This week, the International Myeloma Society (IMS) is hosting its 22nd Annual Meeting—the world’s largest gathering of multiple myeloma researchers and clinicians. The MMRF team is on the ground in To...
themmrf.org
September 18, 2025 at 12:37 PM
Day 1 at #IMS2025 is in the books!
The MMRF team is on the ground in Toronto, bringing you insights from the world’s largest myeloma meeting. From new therapies to strategies for high-risk patients, see our recap of day 1:
👉 themmrf.org/mmrf-blogs/i...
The MMRF team is on the ground in Toronto, bringing you insights from the world’s largest myeloma meeting. From new therapies to strategies for high-risk patients, see our recap of day 1:
👉 themmrf.org/mmrf-blogs/i...
Tecvayli is approved for later line therapies in relapsed/refractory patients. However, studies at #IMS2025 are highlighting the impact bispecifics like Tecvayli can have for newly diagnosed patients. Efficacy results are still very early, but encouraging.
September 17, 2025 at 3:26 PM
Tecvayli is approved for later line therapies in relapsed/refractory patients. However, studies at #IMS2025 are highlighting the impact bispecifics like Tecvayli can have for newly diagnosed patients. Efficacy results are still very early, but encouraging.
Can we amend diagnostic criteria to help identify high risk smoldering patients? Dr. Sagar Lonial weighs in how circulating tumor cells could factor into these criteria #IMS2025
September 17, 2025 at 2:35 PM
Can we amend diagnostic criteria to help identify high risk smoldering patients? Dr. Sagar Lonial weighs in how circulating tumor cells could factor into these criteria #IMS2025
Blenrep has been approved in both the EU 🇪🇺 and Canada 🇨🇦—a meaningful step toward broader global access for myeloma patients.
In the U.S., the FDA review continues. Here’s what patients should know:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF
In the U.S., the FDA review continues. Here’s what patients should know:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF
The State of Blenrep: What Patients Should Know - MMRF
Updated 7/25/2025 Blenrep (belantamab mafodotin) has now been approved for use in both the European Union and Canada—clear signals that international health authorities recognize its clinical value an...
themmrf.org
July 28, 2025 at 7:43 PM
Blenrep has been approved in both the EU 🇪🇺 and Canada 🇨🇦—a meaningful step toward broader global access for myeloma patients.
In the U.S., the FDA review continues. Here’s what patients should know:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF
In the U.S., the FDA review continues. Here’s what patients should know:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF
The FDA has delayed its decision on Blenrep. The MMRF remains hopeful and continues to support approval. Blenrep offers real potential for patients who need accessible, effective care.
Learn more:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF #FDA
Learn more:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF #FDA
The State of Blenrep: What Patients Should Know - MMRF
Updated 7/23/2025 The FDA has announced a delay in its decision on Blenrep (belantamab mafodotin), signaling that more time is needed to complete its review. The deadline for approval is October 23, 2...
themmrf.org
July 23, 2025 at 4:42 PM
The FDA has delayed its decision on Blenrep. The MMRF remains hopeful and continues to support approval. Blenrep offers real potential for patients who need accessible, effective care.
Learn more:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF #FDA
Learn more:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF #FDA
The MMRF weighs in on the latest Blenrep (belantamab mafodotin) news and what it means for patients. With the FDA's decision pending, we’re closely watching next steps. Stay informed and read more 👉 themmrf.org/mmrf-blogs/t... #MultipleMyeloma #Blenrep
The State of Blenrep: What Patients Should Know - MMRF
The MMRF supports FDA approval of Blenrep (belantamab mafodotin) as a meaningful treatment option for patients with relapsed/refractory multiple myeloma. In the coming days, the FDA will decide whethe...
themmrf.org
July 22, 2025 at 1:21 PM
The MMRF weighs in on the latest Blenrep (belantamab mafodotin) news and what it means for patients. With the FDA's decision pending, we’re closely watching next steps. Stay informed and read more 👉 themmrf.org/mmrf-blogs/t... #MultipleMyeloma #Blenrep
Having the right tests is important: they help your doctor confirm a diagnosis, assess the extent of your disease, & monitor progress once you start treatment. Download our Learn Your Labs booklet to better understand the blood tests used in myeloma care: themmrf.org/educational-...
July 16, 2025 at 3:41 PM
Having the right tests is important: they help your doctor confirm a diagnosis, assess the extent of your disease, & monitor progress once you start treatment. Download our Learn Your Labs booklet to better understand the blood tests used in myeloma care: themmrf.org/educational-...
⏰ URGENT: July 15 deadline approaching! #Myeloma patients are running out of options. The MMRF is the only organization solely dedicated to drug discovery and development for these patients. Your donation today will help extend lives. give.themmrf.org/campaign/687... #MMRF #CancerResearch
July 14, 2025 at 3:26 PM
⏰ URGENT: July 15 deadline approaching! #Myeloma patients are running out of options. The MMRF is the only organization solely dedicated to drug discovery and development for these patients. Your donation today will help extend lives. give.themmrf.org/campaign/687... #MMRF #CancerResearch
The FDA just approved a new #Elrexfio dosing schedule. Patients who achieve a sustained response after a set time can now dose every 4 weeks — a shift from the previous standard of biweekly dosing. This is a meaningful step toward reduced treatment burden in #MultipleMyeloma.
July 11, 2025 at 9:52 PM
The FDA just approved a new #Elrexfio dosing schedule. Patients who achieve a sustained response after a set time can now dose every 4 weeks — a shift from the previous standard of biweekly dosing. This is a meaningful step toward reduced treatment burden in #MultipleMyeloma.
The MMRF's Dr. Chuck Acharya will present at the 3rd Annual IMS Workshop on Genomics:
📌 Mapping the interplay between tumor & immune microenvironment – insights from the Immune Atlas Consortium
📅 Jul 12, 9 AM (Lisbon, Portugal)
🔗 Register here: ow.ly/xJct50Wo2fC
📌 Mapping the interplay between tumor & immune microenvironment – insights from the Immune Atlas Consortium
📅 Jul 12, 9 AM (Lisbon, Portugal)
🔗 Register here: ow.ly/xJct50Wo2fC
3rd Annual Workshop on Genomics - International Myeloma Society
Registration Rates In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand session recordi...
ow.ly
July 11, 2025 at 7:03 PM
The MMRF's Dr. Chuck Acharya will present at the 3rd Annual IMS Workshop on Genomics:
📌 Mapping the interplay between tumor & immune microenvironment – insights from the Immune Atlas Consortium
📅 Jul 12, 9 AM (Lisbon, Portugal)
🔗 Register here: ow.ly/xJct50Wo2fC
📌 Mapping the interplay between tumor & immune microenvironment – insights from the Immune Atlas Consortium
📅 Jul 12, 9 AM (Lisbon, Portugal)
🔗 Register here: ow.ly/xJct50Wo2fC
Curious about the latest research in #myeloma treatment? Dr. @FaithEDavies1 & Dr. @OmarNadeemMD break down key updates from #ASCO25 and #EHA2025 during our Patient Livestream on 7/9 at 3pm ET. RSVP here: www.facebook.com/events/14846... #mmsm
FAQs on Myeloma Updates from ASCO & EHA 2025
Other event by Multiple Myeloma Research Foundation - MMRF on Wednesday, July 9 2025
www.facebook.com
July 3, 2025 at 3:06 PM
Curious about the latest research in #myeloma treatment? Dr. @FaithEDavies1 & Dr. @OmarNadeemMD break down key updates from #ASCO25 and #EHA2025 during our Patient Livestream on 7/9 at 3pm ET. RSVP here: www.facebook.com/events/14846... #mmsm
@fda.gov approves bispecific antibody, Lynozyfic (linvoseltamab), for treatment of relapsed/refractory #myeloma patients who have received 4 prior lines of therapy.
investor.regeneron.com/news-release...
Learn more about LINKER-MM1 study. themmrf.org/mmrf-blogs/e...
investor.regeneron.com/news-release...
Learn more about LINKER-MM1 study. themmrf.org/mmrf-blogs/e...
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma | Regeneron Pharmaceuticals Inc.
TARRYTOWN, N.Y. , July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for...
investor.regeneron.com
July 2, 2025 at 4:51 PM
@fda.gov approves bispecific antibody, Lynozyfic (linvoseltamab), for treatment of relapsed/refractory #myeloma patients who have received 4 prior lines of therapy.
investor.regeneron.com/news-release...
Learn more about LINKER-MM1 study. themmrf.org/mmrf-blogs/e...
investor.regeneron.com/news-release...
Learn more about LINKER-MM1 study. themmrf.org/mmrf-blogs/e...
🚨 Calling early-career researchers! The 2025 MMRF Scholars Program is now accepting applications. $400K over 4 years for rising stars in myeloma research.
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
July 1, 2025 at 6:04 PM
🚨 Calling early-career researchers! The 2025 MMRF Scholars Program is now accepting applications. $400K over 4 years for rising stars in myeloma research.
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
The FDA’s removal of REMS for CAR T therapy is a big step forward—improving access for #myeloma patients, especially in rural and underserved areas. It lowers barriers to care and expands access to next-generation CAR T therapies and treatment combinations. #HealthEquity
June 27, 2025 at 9:25 PM
The FDA’s removal of REMS for CAR T therapy is a big step forward—improving access for #myeloma patients, especially in rural and underserved areas. It lowers barriers to care and expands access to next-generation CAR T therapies and treatment combinations. #HealthEquity
This past weekend, Dr. Chuck Acharya, Associate Director of Translational Research at the MMRF, presented at #EHA2025:
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
June 16, 2025 at 8:03 PM
This past weekend, Dr. Chuck Acharya, Associate Director of Translational Research at the MMRF, presented at #EHA2025:
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
📚 NEW CME/CE/CNE Activity for Healthcare Providers
In this free interactive activity, MMRF Chief Medical Officer Dr. Hearn Jay Cho summarizes key evidence on approved and emerging treatments for relapsed/refractory #myeloma. Claim your credit today: www.mycme.com/courses/trea...
In this free interactive activity, MMRF Chief Medical Officer Dr. Hearn Jay Cho summarizes key evidence on approved and emerging treatments for relapsed/refractory #myeloma. Claim your credit today: www.mycme.com/courses/trea...
myCME | Continuing Medical Education
Free online CME & CE for physicians, nurse practitioners, physician assistants & other healthcare professionals in primary care, cardiology, oncology, and other specialties.
www.mycme.com
June 16, 2025 at 3:08 PM
📚 NEW CME/CE/CNE Activity for Healthcare Providers
In this free interactive activity, MMRF Chief Medical Officer Dr. Hearn Jay Cho summarizes key evidence on approved and emerging treatments for relapsed/refractory #myeloma. Claim your credit today: www.mycme.com/courses/trea...
In this free interactive activity, MMRF Chief Medical Officer Dr. Hearn Jay Cho summarizes key evidence on approved and emerging treatments for relapsed/refractory #myeloma. Claim your credit today: www.mycme.com/courses/trea...
TOMORROW: Don't miss our Patient Livestream! Dr. Cindy Varga, PA Jordan Robinson, and a #myeloma patient will answer your questions & share real-life experiences with bispecific antibodies. Set a reminder: www.facebook.com/events/10294... #mmsm
June 10, 2025 at 10:54 PM
TOMORROW: Don't miss our Patient Livestream! Dr. Cindy Varga, PA Jordan Robinson, and a #myeloma patient will answer your questions & share real-life experiences with bispecific antibodies. Set a reminder: www.facebook.com/events/10294... #mmsm
Feeling overwhelmed by your #myeloma journey? You're not alone. Whether you’re smoldering, newly diagnosed, or relapsed/refractory, our mentors are here to offer guidance & share real-life experiences. Connect with a mentor: themmrf.org/support/myel...
June 9, 2025 at 10:05 PM
Feeling overwhelmed by your #myeloma journey? You're not alone. Whether you’re smoldering, newly diagnosed, or relapsed/refractory, our mentors are here to offer guidance & share real-life experiences. Connect with a mentor: themmrf.org/support/myel...
Wondering what bispecific antibody therapy is like? Join Dr. Cindy Varga, PA Jordan Robinson, & a #myeloma patient as they share real experiences & answer your questions.
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
June 5, 2025 at 9:14 PM
Wondering what bispecific antibody therapy is like? Join Dr. Cindy Varga, PA Jordan Robinson, & a #myeloma patient as they share real experiences & answer your questions.
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
Day 2 at #ASCO25 delivered more promising updates for #myeloma patients including 5-year cancer-free results from CAR T-cell therapy, a potential new option with trispecific antibodies, a new way to give Sarclisa, and more.
Read all the highlights here: themmrf.org/mmrf-blogs/m...
Read all the highlights here: themmrf.org/mmrf-blogs/m...
MMRF at ASCO 2025: Day 1 – What Patients Should Know - MMRF
We’re excited to share highlights from the first day of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the year’s most important events in cancer research. This year, res...
themmrf.org
June 4, 2025 at 9:38 PM
Day 2 at #ASCO25 delivered more promising updates for #myeloma patients including 5-year cancer-free results from CAR T-cell therapy, a potential new option with trispecific antibodies, a new way to give Sarclisa, and more.
Read all the highlights here: themmrf.org/mmrf-blogs/m...
Read all the highlights here: themmrf.org/mmrf-blogs/m...
Key takeaways are now available from Day 1 of the #ASCO25 Annual Meeting 🔬. Explore our latest blog to learn about promising updates on Blenrep, advances in treatment for newly diagnosed high-risk #myeloma patients, and more: themmrf.org/mmrf-blogs/m...
MMRF at ASCO 2025: Day 1 – What Patients Should Know - MMRF
We’re excited to share highlights from the first day of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the year’s most important events in cancer research. This year, res...
themmrf.org
June 4, 2025 at 9:01 PM
Key takeaways are now available from Day 1 of the #ASCO25 Annual Meeting 🔬. Explore our latest blog to learn about promising updates on Blenrep, advances in treatment for newly diagnosed high-risk #myeloma patients, and more: themmrf.org/mmrf-blogs/m...
